2C-T-17
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 4-sec-Butylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-sec-butylthiophenethylamine; NIMITZ; Nimitz |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 10–15 hours[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
2C-T-17, also known as 4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz, is a psychedelic drug of the phenethylamine and 2C families.[1] It is taken orally.[1]
2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991.[2] Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-T-17's dose as 60 to 100 mg orally and its duration is 10 to 15 hours.[1] Its onset is 1 hour and peak effects occurred after 3 hours.[1] 2C-T-17 has been described as a "truly heavy psychedelic" but as producing no psychedelic visuals and very little in the way of perceptual changes.[1] User reports described it as having pronounced psychoactive effects, but had difficulty describing exactly what those effects were.[1]
Toxicity
The toxicity of 2C-T-17 is not well-documented. It is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.
Interactions
Pharmacology
Pharmacodynamics
The mechanism of action that produces 2C-T-17's hallucinogenic effects has not been specifically established, however it is most likely to result from action as a serotonin 5-HT2A receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.
Chemistry
2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized.[1] The full chemical name is 2-[4-(2-butyl thio)-2,5-dimethoxy phenyl]ethanamine.[1] The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8.[1]
Synthesis
The chemical synthesis of 2C-T-17 has been described.[1]
History
2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991.[2] Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]
Society and culture
Legal status
Canada
As of October 31, 2016, 2C-T-17 is a controlled substance (Schedule III) in Canada.[3]
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]
United States
2C-T-17 is not illegal, but possession and sales of 2C-T-17 could be prosecuted under the Federal Analog Act in the United States because of its structural similarities to 2C-T-7.
See also
- 2C (psychedelics)
- ASR-3001 (5-MeO-iPALT)
- MiPT
References
- ^ a b c d e f g h i j k l m n Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
- ^ a b Shulgin AT, Shulgin A, Jacob P (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs. 23 (1): 95–96. doi:10.1080/02791072.1991.10472583. eISSN 2159-9777. PMID 1941371. Archived from the original on 2025-07-13.
- ^ "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.
- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.